Obesity and Insulin Resistance Are the Central Issues in Prevention of and Care for Comorbidities

Elisabeth Govers, Elisabeth Govers

Abstract

For a long time the assumption has been that, although weight reduction was necessary and desirable, comorbidities were far more important and needed treatment even if weight loss was not a treatment goal, preferably with medication. This controversy leads to postponement of treatment, and later on causes very intensive medical treatment, thus, raising the health care costs to unacceptable levels, leading to the medicalization of individuals, and a declining of the responsibility of patients for their health, leaving the question of when to regard their own weight as a problem that should be dealt with up to individuals. The central problem is insulin resistance, which leads to a cascade of health problems. This condition should be diagnosed in primary practice and obesity clinics to ensure a better, tailor-made treatment for patients. Treatment should start at the earliest stage possible, when comorbidities are still reversible and includes a personalized dietary advice and counseling, preferably by a dietitian, to tackle insulin resistance. An exercise program is part of the treatment.

Keywords: comorbidities; dietitian; insulin resistance; metabolic syndrome; obesity; treatment.

References

    1. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900–917. doi: 10.1016/j.cell.2010.02.034.
    1. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Ann. Rev. Immunol. 2011;29:415–445. doi: 10.1146/annurev-immunol-031210-101322.
    1. Nakamura T., Furuhashi M., Li P., Cao H., Tuncman G., Sonenberg N., Gorgun C.Z., Hotamisligil G.S. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell. 2010;140:338–348. doi: 10.1016/j.cell.2010.01.001.
    1. Hummasti S., Hotamisligil G.S. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ. Res. 2010;107:579–591. doi: 10.1161/CIRCRESAHA.110.225698.
    1. Yang L., Li P., Fu S., Calay E.S., Hotamisligi G.S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010;11:467–478. doi: 10.1016/j.cmet.2010.04.005.
    1. Reaven G.M. Insulin resistance and its consequences: Type 2 diabetes mellitus and coronary heart disease. In: LeRoith D., Taylor S.I., Olefsky J.M., editors. Diabetes Mellitus: A Fundamental and Clinical Text. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2000. pp. 604–615.
    1. Bakhai A. Adipokines-targeting a root cause of cardiometabolic risk. QJM. 2008;101:767–776. doi: 10.1093/qjmed/hcn066.
    1. De Fronzo R.A. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth. J. Med. 1997;50:191–197. doi: 10.1016/S0300-2977(97)00012-0.
    1. Chapman M.J., Sposito A.C. Hypertension and dyslipidaemia in obesity and insulin resistance: Pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol. Ther. 2008;117:354–373. doi: 10.1016/j.pharmthera.2007.10.004.
    1. Arruda A.P., Pers B.M., Parlakgül G., Güney E., Inouye K., Hotamisligil G.S. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat. Med. 2014;20:1427–1435. doi: 10.1038/nm.3735.
    1. Wolfs M.G.M., Gruben N., Rensen S.S., Verdam F.J., Greve J.W., Driessen A., Wijmenga C., Buurman W.A., Franke L., Scheja L., et al. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr. Diabetes. 2015 doi: 10.1038/nutd.2014.43.
    1. Locke A.E., Kahali B., Berndt S.I., Justice A.E., Pers T.H., Day F.R., Powell C., Vedantam S., Buchkovich M.L., Yang J., et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206. doi: 10.1038/nature14177.
    1. Croteau-Chonka D.C., Ferreira T., Locke A.E., Mägi R., Strawbridge R.J., Pers T.H., Fischer K., Justice A.E., Workalemahu T., Wu J.M., et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518:187–196.
    1. Goossens G.H. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Nat. Med. 2014;20:1427–1435. doi: 10.1016/j.physbeh.2007.10.010.
    1. Roberts C.K., Hevener A.L., Barnard R.J. Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training. Compr. Physiol. 2013;3:1–58.
    1. Barnard R.J. Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am. J. Clin. Nutr. 2007;86:s889–s893.
    1. Sánchez Jiménez J., Herrero Espinet F.J., Mengibar Garrido J.M., Roca Antonio J., Peños Mayor S., Peñas Boira Mdel M., Roca Comas A., Ballester Martínez A. Asthma and insulin resistance in obese children and adolescents. Pediatr. Allergy Immunol. 2014;25:699–705. doi: 10.1111/pai.12294.
    1. Naik D., Joshi A., Paul T.V., Thomas N. Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat. Indian J. Endocrinol. Metab. 2014;18:608–616.
    1. Ma L., Wang J., Li Y. Insulin resistance and cognitive dysfunction. Clin. Chim. Acta. 2015;444:18–23. doi: 10.1016/j.cca.2015.01.027.
    1. Kalmijn S., Foley D., White L., Burchfiel C.M., Curb J.D., Petrovitch H., Ross G.W., Havlik R.J., Launer L.J. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: The honolulu-asia aging study. Arterioscler. Thromb. Vasc. Biol. 2000;20:2255–2260. doi: 10.1161/01.ATV.20.10.2255.
    1. Vgontzas A.N., Bixler E.O., Chrousos G.P. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med. Rev. 2005;9:211–224. doi: 10.1016/j.smrv.2005.01.006.
    1. Brandsma E., Houben T., Fu J., Shiri-Sverdlov R., Hofker M.H. The immunity-diet-microbiota axis in the development of metabolic syndrome. Curr. Opin. Lipidol. 2015;26:73–81. doi: 10.1097/MOL.0000000000000154.
    1. Paolella G., Mandato C., Pierri L., Poeta M., di Stasi M., Vajro P. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014;20:15518–15531. doi: 10.3748/wjg.v20.i42.15518.
    1. Pereira M.A., Jacobs D.R., Jr., van Horn L., Slattery M.L., Kartashov A.I., Ludwig D.S. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: The CARDIA Study. JAMA. 2002;287:2081–2089. doi: 10.1001/jama.287.16.2081.
    1. Wildman R.P., Muntner P., Reynolds K., McGinn A.P., Rajpathak S., Wylie-Rosett J., Sowers M.R. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004) Arch. Intern. Med. 2008;168:1617–1624. doi: 10.1001/archinte.168.15.1617.
    1. Bak M., Fransen A., Janssen J., van Os J., Drukker M. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS ONE. 2014;9:94–112. doi: 10.1371/journal.pone.0094112.
    1. Stahl S., Mignon L., Meyer J.M. Which comes first: Atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr. Scand. 2009;119:171–179. doi: 10.1111/j.1600-0447.2008.01334.x.
    1. Tull E.S., Doswell W.M., Cort M.A. Spirituality moderates the relationship of psychosocial stress to metabolic risk factors among Afro-Caribbean immigrants in the US Virgin Islands. J. Racial Ethn. Health Disparities. 2015;2:132–138. doi: 10.1007/s40615-014-0056-9.
    1. World Health Organization . 2008–2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. WHO Press; Geneva, Switzerland: 2008.
    1. Saha S., Gerdtham U.G., Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int. J. Environ. Res. Public Health. 2010;7:3150–3195. doi: 10.3390/ijerph7083150.
    1. Radl K., Ianuale C., Boccia S. A systematic review of the cost-effectiveness of lifestyle modification as primary prevention intervention for type 2 diabetes mellitus. Epidemiol. Biostat. Public Health. 2013;10:e8846-1–e8846-8.
    1. Diabetes Prevention Program Research Group. Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J., Brenneman A.T., Brown-Friday J.O., Goldberg R., Venditti E., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.
    1. Perreault L., Kahn S.E., Christophi C.A., Knowler W.C., Hamman R.F., Diabetes Prevention Program Research Group Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009;32:1583–1588. doi: 10.2337/dc09-0523.
    1. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344:1343–1350. doi: 10.1056/NEJM200105033441801.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA. 2001;285:2486–2497.
    1. Zadeh-Vakili A., Tehrani F.R., Hosseinpanah F. Waist circumference and insulin resistance: A community based cross sectional study on reproductive aged Iranian women. Diabetol. Metab. Syndr. 2011;3 doi: 10.1186/1758-5996-3-18.
    1. Iantorno M., Campia U., di Daniele N., Nistico S., Forleo G.B., Cardillo C., Tesauro M. Obesity, inflammation and endothelial dysfunction. J. Biol. Regul. Homeost. Agents. 2014;28:169–176.
    1. Aron-Wisnewsky J., Tordjman J., Poitou C., Darakhshan F., Hugol D., Basdevant A., Aissat A., Guerre-Millo M., Clement K. Human adipose tissue macrophages: M1 and M2 cell surface markers in subcutaneous and omental depots and after weight loss. J. Clin. Endocrinol. Metab. 2009;94:4619–4623. doi: 10.1210/jc.2009-0925.
    1. Kawanishi N., Yano H., Yokogawa Y., Suzuki K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc. Immunol. Rev. 2010;16:105–118.
    1. Kovacikova M., Sengenes C., Kovacova Z., Siklova-Vitkova M., Klimcakova E., Polak J., Rossmeislova L., Bajzova M., Hejnova J., Hnevkovska Z., et al. Dietary intervention-induced weight loss decreases macrophage content in adipose tissue of obese women. Int. J. Obes. 2010;35:91–98. doi: 10.1038/ijo.2010.112.
    1. Hu T., Bazzano L.A. The low-carbohydrate diet and cardiovascular risk-factors. Evidence from epidemiologic studies. Nutr. Metab. Cardiovasc. Dis. 2014;24:337–437. doi: 10.1016/j.numecd.2013.12.008.
    1. Naude C.E., Schoonees A., Senekal M., Young T., Garner P., Volmink J. Low carbohydrate vs. isoenergetic balanced diets for reducing weight and cardiovascular risk: A systematic review and meta-analysis. PLoS ONE. 2014;9:e100652. doi: 10.1371/journal.pone.0100652.
    1. Ley S.H., Hamdy O., Mohan V., Hu F.B. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet. 2014;383:1999–2007. doi: 10.1016/S0140-6736(14)60613-9.
    1. Ajala O., English P., Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am. J. Clin. Nutr. 2013;97:505–516. doi: 10.3945/ajcn.112.042457.
    1. Hinderliter A.L., Sherwood A., Craighead L.W., Lin P.H., Watkins L., Babyak M.A., Blumenthal J.A. The long-term effects of lifestyle change on blood pressure: One-year follow-up of the ENCORE study. Am. J. Hypertens. 2014;27:734–741. doi: 10.1093/ajh/hpt183.
    1. Blumenthal J.A., Babyak M.A., Hinderliter A., Watkins L.L., Craighead L., Lin P.H., Caccia C. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: The ENCORE study. Arch. Intern. Med. 2010;170:126–135. doi: 10.1001/archinternmed.2009.470.
    1. Bozzetto L., Prinster A., Annuzzi G., Costagliola L., Mangione A., Vitelli A., Mazzarella R., Longobardo M., Mancini M., Vigorito C., et al. Liver fat Is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012;35:1429–1435. doi: 10.2337/dc12-0033.
    1. Feinman R.D., Vernon M.C., Westman B.C. Low carbohydrate diets in family practice: What can we learn from an internet-based support group. Nutr. J. 2006;5 doi: 10.1186/1475-2891-5-26.
    1. Liu S., Willett W.C., Stampfer M.J., Hu F.B., Franz M., Sampson L., Hennekens C.H., Manson J.E. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am. J. Clin. Nutr. 2000;71:1455–1461.
    1. Layman D.K. Dietary guidelines should reflect new understanding about adult protein needs. Nutr. Metab. 2009;6 doi: 10.1186/1743-7075-6-12.
    1. Dibaba D.T., Xun P., Fly A.D., Yokota K., He K. Dietary magnesium intake and risk of metabolic syndrome: A meta-analysis. Diabet Med. 2014;31:1301–1309. doi: 10.1111/dme.12537.
    1. Ford E.S., Ajani U.A., McGuire L.C., Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28:1228–1230. doi: 10.2337/diacare.28.5.1228.
    1. Vieth R. Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/mL) Best Pract. Res. Clin. Endocrinol. Metab. 2011;25:681–691. doi: 10.1016/j.beem.2011.06.009.
    1. Styskala J.L. Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models. Free Radic. Biol. Med. 2012;52:46–58. doi: 10.1016/j.freeradbiomed.2011.10.441.
    1. Ludwig D.S., Pereira M.A., Kroenke C.H., Hilner J.E., van Horn L., Slattery M.L., Jacobs D.R. Dietary fiber, weight gain, and cardiovascular risk disease factors in young adults. JAMA. 1999;282:1539–1546. doi: 10.1001/jama.282.16.1539.
    1. Balducci S., Zanuso S., Nicolucci A., de Feo P., Cavallo S., Cardelli P., Fallucca S., Alessi E., Fallucca F., Pugliese G. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: A randomized controlled trial: The Italian Diabetes and Exercise Study (IDES) Arch. Intern. Med. 2010;170:1794–1803. doi: 10.1001/archinternmed.2010.380.
    1. Kasapis C., Thompson P.D. The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J. Am. Coll. Cardiol. 2005;45:1563–1569. doi: 10.1016/j.jacc.2004.12.077.
    1. Petersen A.M., Pedersen B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 2005;98:1154–1162. doi: 10.1152/japplphysiol.00164.2004.
    1. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005;26:439–451. doi: 10.1210/er.2005-0005.
    1. Flynn M.G., McFarlin B.K. Toll-like receptor 4: Link to the anti-inflammatory effects of exercise? Exerc. Sport Sci. Rev. 2006;34:176–181. doi: 10.1249/01.jes.0000240027.22749.14.
    1. Davis J.E., Gabler N.K., Walker-Daniels J., Spurlock M.E. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity. 2008;16:1248–1255. doi: 10.1038/oby.2008.210.
    1. Saberi M., Woods N.B., de Luca C., Schenk S., Lu J.C., Bandyopadhyay G., Verma I.M., Olefsky J.M. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 2009;10:419–429. doi: 10.1016/j.cmet.2009.09.006.
    1. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., Araujo E.P., Vassallo J., Curi R., Velloso L.A., et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56:1986–1998. doi: 10.2337/db06-1595.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren